Cargando…

Protective activity of propofol, Diprivan and intralipid against active oxygen species.

We separately studied the antioxidant properties of propofol (PPF), Diprivan (the commercial form of PPF) and intralipid (IL) (the vehicle solution of PPF in Diprivan) on active oxygen species produced by phorbol myristate acetate (10(-6) M)-stimulated human polymorphonuclear leukocytes (PMN: 5 x 10...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathy-Hartert, M, Deby-Dupont, G, Hans, P, Deby, C, Lamy, M
Formato: Texto
Lenguaje:English
Publicado: 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781863/
https://www.ncbi.nlm.nih.gov/pubmed/9883967
_version_ 1782131994107314176
author Mathy-Hartert, M
Deby-Dupont, G
Hans, P
Deby, C
Lamy, M
author_facet Mathy-Hartert, M
Deby-Dupont, G
Hans, P
Deby, C
Lamy, M
author_sort Mathy-Hartert, M
collection PubMed
description We separately studied the antioxidant properties of propofol (PPF), Diprivan (the commercial form of PPF) and intralipid (IL) (the vehicle solution of PPF in Diprivan) on active oxygen species produced by phorbol myristate acetate (10(-6) M)-stimulated human polymorphonuclear leukocytes (PMN: 5 x 10(5) cells/assay), human endothelial cells (5 x 10(5) cells/assay) or cell-free systems (NaOCl or H2O2/peroxidase systems), using luminol (10(-4) M)-enhanced chemiluminescence (CL). We also studied the protective effects of Diprivan on endothelial cells submitted to an oxidant stress induced by H2O2/MPO system: cytotoxicity was assessed by the release of preincorporated 51Cr. Propofol inhibited the CL produced by stimulated PMN in a dose dependent manner (until 5 x 10(-5) M, a clinically relevant concentration), while Diprivan and IL were not dose-dependent inhibitors. The CL produced by endothelial cells was dose-dependently inhibited by Diprivan and PPF, and weakly by IL (not dose-dependent). In cell free systems, dose-dependent inhibitions were obtained for the three products with a lower effect for IL. Diprivan efficaciously protected endothelial cells submitted to an oxidant stress, while IL was ineffective. By HPLC, we demonstrated that PPF was not incorporated into the cells. The drug thus acted by scavenging the active oxygen species released in the extracellular medium. IL acted in the same manner, but was a less powerful antioxidant.
format Text
id pubmed-1781863
institution National Center for Biotechnology Information
language English
publishDate 1998
record_format MEDLINE/PubMed
spelling pubmed-17818632007-01-25 Protective activity of propofol, Diprivan and intralipid against active oxygen species. Mathy-Hartert, M Deby-Dupont, G Hans, P Deby, C Lamy, M Mediators Inflamm Research Article We separately studied the antioxidant properties of propofol (PPF), Diprivan (the commercial form of PPF) and intralipid (IL) (the vehicle solution of PPF in Diprivan) on active oxygen species produced by phorbol myristate acetate (10(-6) M)-stimulated human polymorphonuclear leukocytes (PMN: 5 x 10(5) cells/assay), human endothelial cells (5 x 10(5) cells/assay) or cell-free systems (NaOCl or H2O2/peroxidase systems), using luminol (10(-4) M)-enhanced chemiluminescence (CL). We also studied the protective effects of Diprivan on endothelial cells submitted to an oxidant stress induced by H2O2/MPO system: cytotoxicity was assessed by the release of preincorporated 51Cr. Propofol inhibited the CL produced by stimulated PMN in a dose dependent manner (until 5 x 10(-5) M, a clinically relevant concentration), while Diprivan and IL were not dose-dependent inhibitors. The CL produced by endothelial cells was dose-dependently inhibited by Diprivan and PPF, and weakly by IL (not dose-dependent). In cell free systems, dose-dependent inhibitions were obtained for the three products with a lower effect for IL. Diprivan efficaciously protected endothelial cells submitted to an oxidant stress, while IL was ineffective. By HPLC, we demonstrated that PPF was not incorporated into the cells. The drug thus acted by scavenging the active oxygen species released in the extracellular medium. IL acted in the same manner, but was a less powerful antioxidant. 1998 /pmc/articles/PMC1781863/ /pubmed/9883967 Text en
spellingShingle Research Article
Mathy-Hartert, M
Deby-Dupont, G
Hans, P
Deby, C
Lamy, M
Protective activity of propofol, Diprivan and intralipid against active oxygen species.
title Protective activity of propofol, Diprivan and intralipid against active oxygen species.
title_full Protective activity of propofol, Diprivan and intralipid against active oxygen species.
title_fullStr Protective activity of propofol, Diprivan and intralipid against active oxygen species.
title_full_unstemmed Protective activity of propofol, Diprivan and intralipid against active oxygen species.
title_short Protective activity of propofol, Diprivan and intralipid against active oxygen species.
title_sort protective activity of propofol, diprivan and intralipid against active oxygen species.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781863/
https://www.ncbi.nlm.nih.gov/pubmed/9883967
work_keys_str_mv AT mathyhartertm protectiveactivityofpropofoldiprivanandintralipidagainstactiveoxygenspecies
AT debydupontg protectiveactivityofpropofoldiprivanandintralipidagainstactiveoxygenspecies
AT hansp protectiveactivityofpropofoldiprivanandintralipidagainstactiveoxygenspecies
AT debyc protectiveactivityofpropofoldiprivanandintralipidagainstactiveoxygenspecies
AT lamym protectiveactivityofpropofoldiprivanandintralipidagainstactiveoxygenspecies